Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
13therapeutics Inc
AIM ImmunoTech Inc
Aston Sci Co Ltd
Glysantis Inc
HDT Bio Corp
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Tollys SAS
Wyvern Pharmaceuticals Inc
Yisheng Biopharma Co Ltd
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
AST-065 - Drug Profile
Product Description
Mechanism Of Action
BO-112 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GLY-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HDT-401 - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-7 - Drug Profile
Product Description
Mechanism Of Action
Poly-ICLC - Drug Profile
Product Description
Mechanism Of Action
History of Events
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize TLR-3 for Gastrointestil Syndrome - Drug Profile
Product Description
Mechanism Of Action
TL-532 - Drug Profile
Product Description
Mechanism Of Action
History of Events
WYV-ONC - Drug Profile
Product Description
Mechanism Of Action
YSHBV-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
Mar 09, 2022: AIM ImmunoTech announces abstract from university of Pittsburgh medical center accepted for presentation at the AACR 2022 annual meeting
Mar 09, 2022: AIM ImmunoTech announces abstracts from Roswell Park Comprehensive Cancer Center accepted for presentation in a late-breaking poster session at the AACR 2022 annual meeting
Mar 08, 2022: AIM ImmunoTech announces publication of positive data from late-stage pancreatic cancer Early Access Program (EAP) in the cancers special issue: combition and innovative therapies for Pancreatic Cancer
Jan 24, 2022: AIM ImmunoTech announces publication of positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
Dec 09, 2021: AIM ImmunoTech’s Ampligen safety data presented at Eighth European Scientific Working Group on Influenza
Dec 02, 2021: Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO112 + STING agonist published in Jourl for ImmunoTherapy of Cancer
Nov 12, 2021: Positive phase 2b results in 2nd line melanoma
Oct 19, 2021: AIM ImmunoTech submits IND and accompanying fast track application for phase 2 trial of Ampligen in patients with locally advanced or metastatic late-stage pancreatic cancer
Oct 06, 2021: AIM ImmunoTech publishes phase 1 clinical study data supporting the safety of Ampligen as an intrasal therapy
Oct 04, 2021: AIM ImmunoTech provides clinical updates on planned phase 2 study of Ampligen in patients with locally advanced or metastatic late-stage pancreatic cancer
Sep 29, 2021: AIM seeks FDA approval to conduct Phase II Covid-19 therapy trials
Sep 27, 2021: AIM ImmunoTech files provisiol patent application for Ampligen as an early-onset intrasal therapy that may also confer enhanced immunity to a wide range of respiratory viruses
Sep 21, 2021: AIM ImmunoTech announces positive progress on requested FDA meeting for proposed Ampligen clinical trial in post-COVID-19 cognitive dysfunction
Sep 20, 2021: AIM ImmunoTech provides an update on its pending phase 2a human challenge trial using its drug Ampligen
Sep 09, 2021: AIM seeks FDA approval for Phase II trial of Ampligen for Covid-19
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 13therapeutics Inc, 2022
Pipeline by AIM ImmunoTech Inc, 2022
Pipeline by Aston Sci Co Ltd, 2022
Pipeline by Glysantis Inc, 2022
Pipeline by HDT Bio Corp, 2022
Pipeline by Highlight Therapeutics SL, 2022
Pipeline by Oncovir Inc, 2022
Pipeline by PrEP Biopharm Ltd, 2022
Pipeline by Tollys SAS, 2022
Pipeline by Wyvern Pharmaceuticals Inc, 2022
Pipeline by Yisheng Biopharma Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022